 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12...1314151617181920212223...2728» |
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial completion date, Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
Trial completion date: Oct 2018 --> Sep 2019 | Trial primary completion date: Oct 2018 --> Sep 2019
- ||||||| anastrozole / Generic mfg., tamoxifen / Generic mfg., zoledronic acid / Generic mfg.
Trial completion, Trial completion date, Combination therapy: ABCSG-12: Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid (clinicaltrials.gov) - Dec 20, 2018
P3, N=1803, Completed, Sponsor: Austrian Breast & Colorectal Cancer Study Group
Trial completion date: Oct 2018 --> Sep 2019 | Trial primary completion date: Oct 2018 --> Sep 2019 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Jun 2018
- || goserelin acetate / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX (clinicaltrials.gov) - Dec 17, 2018
P=N/A, N=500, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Jun 2018 Trial completion date: Mar 2019 --> Feb 2020 | Trial primary completion date: Mar 2019 --> Feb 2020
- |||| goserelin acetate / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Head-to-Head: LARES: To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (clinicaltrials.gov) - Dec 3, 2018
P3, N=168, Not yet recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2019 --> Feb 2020 | Trial primary completion date: Mar 2019 --> Feb 2020 Trial completion date: Jun 2020 --> Dec 2020 | Initiation date: Nov 2018 --> Apr 2019 | Trial primary completion date: Jun 2020 --> Dec 2020
- | goserelin acetate / Generic mfg.
Trial completion date, Trial primary completion date: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females (clinicaltrials.gov) - Nov 29, 2018
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2020 --> Dec 2020 | Initiation date: Nov 2018 --> Apr 2019 | Trial primary completion date: Jun 2020 --> Dec 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Enrollment open, Trial initiation date: ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Nov 23, 2018
P2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Nov 2018
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Nov 21, 2018
P1, N=88, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Nov 2018 Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2020
- | goserelin acetate / Generic mfg.
Enrollment closed, Combination therapy: Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 20, 2018
P2, N=12, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2020 Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Trial primary completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Nov 15, 2018
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Mar 2019
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Nov 8, 2018
P3, N=3258, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Mar 2019 Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Trial completion date: Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Nov 5, 2018
P3, N=226, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012 Trial completion date: Sep 2018 --> Sep 2019
- ||||| exemestane / Generic mfg.
Enrollment status, Trial completion date, Trial initiation date, Trial primary completion date: A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations ?STEP? (clinicaltrials.gov) - Oct 31, 2018
P3, N=300, Enrolling by invitation, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Trial completion date: Sep 2018 --> Sep 2019 Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Oct 2023 | Initiation date: Apr 2018 --> Aug 2018 | Trial primary completion date: Jun 2023 --> Oct 2023
- | goserelin acetate / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose (clinicaltrials.gov) - Oct 29, 2018
P=N/A, N=40, Recruiting, Sponsor: Norwegian School of Sport Sciences
Recruiting --> Enrolling by invitation | Trial completion date: Jun 2023 --> Oct 2023 | Initiation date: Apr 2018 --> Aug 2018 | Trial primary completion date: Jun 2023 --> Oct 2023 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Sep 2018 | Trial primary completion date: Sep 2018 --> Apr 2019
- | goserelin acetate / Generic mfg., triptorelin / Generic mfg.
New trial, Surgery: Surgery and ART For Endometrioma (clinicaltrials.gov) - Oct 24, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Universit
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Metastases: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (clinicaltrials.gov) - Oct 22, 2018
P3, N=600, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Sep 2018 | Trial primary completion date: Sep 2018 --> Apr 2019 Recruiting --> Active, not recruiting
- | Piqray (alpelisib) / Novartis, buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion, Metastases: B-YOND: A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 15, 2018
P1, N=40, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: PALOMA3: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) (clinicaltrials.gov) - Oct 9, 2018
P3, N=521, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial completion date: Jan 2019 --> Jan 2020
- || Enrollment closed, PARP Biomarker: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (clinicaltrials.gov) - Oct 9, 2018
P2, N=200, Active, not recruiting, Sponsor: Haukeland University Hospital
Trial completion date: Jan 2019 --> Jan 2020 Recruiting --> Active, not recruiting
- | goserelin acetate / Generic mfg., carboplatin / Generic mfg., docetaxel / Generic mfg.
New P2 trial: STAMP: Selective Treatment According to Molecular Subtype of Prostate Cancer (clinicaltrials.gov) - Oct 3, 2018
P2, N=300, Recruiting, Sponsor: Tianjin Medical University Second Hospital
- | goserelin acetate / Generic mfg.
Trial completion date, Combination therapy: Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=12, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Dec 2018 --> Sep 2019
- ||||| tamoxifen / Generic mfg.
Trial completion: GBG54: Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (clinicaltrials.gov) - Sep 19, 2018
P3, N=56, Completed, Sponsor: German Breast Group
Trial completion date: Dec 2018 --> Sep 2019 Active, not recruiting --> Completed
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati, Firmagon (degarelix) / Astellas, Ferring
New P3 trial, Surgery, Metastases: S1802: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 18, 2018
P3, N=1273, Recruiting, Sponsor: Southwest Oncology Group
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Enrollment change, Combination therapy: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Sep 17, 2018
P2, N=310, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=200 --> 310
- | Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - Sep 14, 2018
P2, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
- | tamoxifen / Generic mfg.
New P3 trial: Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) (clinicaltrials.gov) - Sep 11, 2018
P3, N=224, Recruiting, Sponsor: Seoul National University Hospital
- |||||||| goserelin acetate / Generic mfg.
New P3 trial, Head-to-Head: LARES: To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. (clinicaltrials.gov) - Sep 5, 2018
P3, N=168, Not yet recruiting, Sponsor: AstraZeneca
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Aug 25, 2018
P1, N=25, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
N=200 --> 310 Trial primary completion date: Dec 2018 --> Jul 2017
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 15, 2018
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Trial primary completion date: Dec 2018 --> Jul 2017 Trial primary completion date: Jul 2018 --> Oct 2018
- | Erleada (apalutamide) / J&J
Trial completion date, Trial initiation date, Trial primary completion date: Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=64, Not yet recruiting, Sponsor: Instituto do Cancer do Estado de S
Trial primary completion date: Jul 2018 --> Oct 2018 Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Apr 2019 --> Mar 2020 | Initiation date: Jun 2017 --> Oct 2018
- |||| Ibrance (palbociclib) / Pfizer
New P2 trial: Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=76, Not yet recruiting, Sponsor: NSABP Foundation Inc
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Trial primary completion date, Metastases: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 6, 2018
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Apr 2019 --> Mar 2020 | Initiation date: Jun 2017 --> Oct 2018 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Trial completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Jul 20, 2018
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Oct 2024 --> Jul 2024
- | fulvestrant / Generic mfg.
New P4 trial, Metastases: Fulvestrant in Metastatic Breast Cancer (clinicaltrials.gov) - Jul 19, 2018
P4, N=30, Not yet recruiting, Sponsor: Assiut University
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 18, 2018
P3, N=660, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2024 --> Jul 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Aug 2017
- | goserelin acetate / Generic mfg., abiraterone acetate / Generic mfg., bicalutamide / Generic mfg.
New P1/2 trial, Metastases: A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer (clinicaltrials.gov) - Jul 15, 2018
P1/2, N=60, Not yet recruiting, Sponsor: Guangzhou University of Traditional Chinese Medicine
- || Trial completion: Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer (clinicaltrials.gov) - Jul 13, 2018
P2, N=35, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Aug 2017 Active, not recruiting --> Completed
- | Kisqali (ribociclib) / Novartis
Enrollment open, Trial primary completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 13, 2018
P3, N=660, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Aug 2019 --> Jul 2018 | Active, not recruiting --> Recruiting
- | Xofigo (radium Ra-223 dichloride) / Bayer
Trial initiation date, Combination therapy, Metastases: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Jul 13, 2018
P2, N=24, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Aug 2019 --> Jul 2018 | Active, not recruiting --> Recruiting Initiation date: Jun 2018 --> Sep 2018
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Surgery: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Jul 10, 2018
P3, N=788, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: Jun 2018 --> Sep 2018 Trial primary completion date: Jun 2018 --> Oct 2018
- | abiraterone acetate / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy (clinicaltrials.gov) - Jul 10, 2018
P2, N=46, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jun 2018 --> Oct 2018 Trial completion date: Jan 2019 --> Sep 2018 | Trial primary completion date: Jan 2019 --> Sep 2018
- | Trial completion date, Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Jul 9, 2018
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jan 2019 --> Sep 2018 | Trial primary completion date: Jan 2019 --> Sep 2018 Trial completion date: Jul 2023 --> Oct 2024 | Trial primary completion date: Jul 2018 --> Nov 2019
- || Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
New P2 trial: ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Jun 28, 2018
P2, N=40, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- | MK-2206 / Merck (MSD), anastrozole / Generic mfg.
Clinical, P2 data, Journal: A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer. (Pubmed Central) - Jun 24, 2018
Trial completion date: Jul 2023 --> Oct 2024 | Trial primary completion date: Jul 2018 --> Nov 2019 MK2206 is unlikely to add to the efficacy of anastrozole alone in PIK3CA mutant ER+ breast cancer and should not be studied further in the target patient population.
- | docetaxel / Generic mfg.
Trial completion, Combination therapy: Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy (clinicaltrials.gov) - Jun 14, 2018
P2, N=80, Completed, Sponsor: Radiation Therapy Oncology Group
MK2206 is unlikely to add to the efficacy of anastrozole alone in PIK3CA mutant ER+ breast cancer and should not be studied further in the target patient population. Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer, gedatolisib (PF-05212384) / Celcuity
Trial completion date, Trial primary completion date: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer (clinicaltrials.gov) - Jun 12, 2018
P1, N=18, Recruiting, Sponsor: Hoffman Oncology
Active, not recruiting --> Completed Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Jan 2019
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: RIBECCA: Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 12, 2018
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Jan 2019 Trial primary completion date: Sep 2019 --> Nov 2018
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 8, 2018
P3, N=312, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2019 --> Nov 2018 Trial primary completion date: Mar 2018 --> Aug 2021
- || Trial completion: Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer (clinicaltrials.gov) - Jun 3, 2018
P2, N=32, Completed, Sponsor: University of Washington
Trial primary completion date: Mar 2018 --> Aug 2021 Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer, fulvestrant / Generic mfg.
Clinical, Journal: Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (Pubmed Central) - May 23, 2018
P3
In pretreated premenopausal women with hormone receptor-positive advanced breast cancer, palbociclib plus fulvestrant and goserelin (luteinizing hormone-releasing hormone [LHRH] agonist) treatment almost doubled median progression-free survival (PFS) and significantly increased the objective response rate versus endocrine monotherapy, achieving results comparable to those reported for chemotherapy without apparently interfering with LHRH agonist-induced ovarian suppression. The significant PFS gain and tolerable safety profile strongly support use of this regimen in premenopausal women with endocrine-resistant disease who could possibly delay chemotherapy.
- | goserelin acetate / Generic mfg.
Enrollment open: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females (clinicaltrials.gov) - Apr 27, 2018
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
The significant PFS gain and tolerable safety profile strongly support use of this regimen in premenopausal women with endocrine-resistant disease who could possibly delay chemotherapy. Not yet recruiting --> Recruiting